LONDON (Reuters) - Britain's health cost watchdog NICE sparked a major row on Thursday by snubbing a pricey new prostate cancer pill discovered at the country's top cancer research centre, a decision critics said was bad for patients and research. If the draft ruling is upheld after further consultation, Zytiga, which is marketed by Johnson & Johnson, will not be reimbursed on the state-run ...